Inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9512115
APP PUB NO 20160031869A1
SERIAL NO

14775785

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
VIVORYON THERAPEUTICS N VWEINBERGWEG 22 HALLE (SAALE) 06120

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Buchholz, Mirko Halle/Saale, DE 26 330
Demuth, Hans-Ulrich Halle/Saale, DE 116 1907
Heiser, Ulrich Halle/Saale, DE 66 916
Meyer, Antje Halle/Saale, DE 6 30
Sommer, Robert Magdeburg, DE 10 42

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 6, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00